BlossomHill Therapeutics, Inc. Research and Development Expense
BlossomHill Therapeutics, Inc. (BLSM) reported Research and Development Expense of $21.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-18.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-18
- BlossomHill Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $21.36M, a 70.43% increase year-over-year.
- BlossomHill Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $12.53M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $21.36M 10-Q · filed 2026-09-18 | $41.26M 10-Q · filed 2026-09-18 |
| 2025-06-30 | $12.53M 10-Q · filed 2026-09-18 | $22.10M 10-Q · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |